Cardiovascular drugs

(BQ) Part 1 book "Cardiovascular diseases - From molecular pharmacology to evidence-Based therapeutics" presents the following contents: General introduction, dyslipidemias, hypertension and multitasking cardiovascular drugs.

Our main purpose in editing this book is to provide the health care practitioner
with general clinical practical guidelines regarding the use of pediatric
cardiovascular drugs. We also intend to provide an overview of basic pediatric
cardiovascular principles. We realize the need for a pocket reference handbook that
is tailored to meet the daily challenges of practitioners that care for pediatric
cardiac patients.

Cardiovascular disease, including coronary heart disease, strokes and diseases of other arteries, is a major
cause of early death and disability. For many years the major markers of disease risk have been well recognised:
these include high blood cholesterol levels and smoking. But it has also been recognised that these markers do
not account for all cardiovascular risk. Furthermore, treatments that are highly effective in altering these
markers, for instance the ‘statin’ drugs used to lower cholesterol, do not remove risk entirely: typically they
reduce it by about 30% or less.

(BQ) Part 1 book "Principles of pharmacology - The pathophysiologic basis of drug therapy" presentation of content: Fundamental principles of pharmacology, principles of neuropharmacology (fundamental principles of neuropharmacology, principles of autonomic and peripheral nervous system pharmacology, principles of central nervous system pharmacology), principles of cardiovascular pharmacology.

The last quarter of a century has seen dramatic
developments in the management of cardiovascular
diseases. Besides the pioneering developments in
the medical management of cardiovascular disorders
the field of interventional cardiology has also emerged
as a major discipline with a huge impact on the
clinical management of acute coronary syndrome,
chronic coronary artery disease, congestive heart
failure, and peripheral vascular and valvular diseases.

The second chapter case study by Rosso et al. presents a medical survey that tests
professional drivers for the presence of various psychoactive substances. Positives
were identified by using a commercially available immunoassay rapid kit test which
indicates consumption of psychoactive drugs. This is of interest and important since
the dependence on drugs may pose a risk to drivers in their profession affecting their
reaction time and driving judgment. This is one of the first and important
contributions to the literature in this area.

Anyone who administers drugs acting on cardiovascular adrenergic mechanisms requires an understanding of how they act in order to use them to the best advantage and with safety. Adrenergic mechanisms Classification of sympathomimetics: by mode of action and selectivity for adrenoceptors Individual sympathomimetics Mucosal decongestants Shock Chronic orthostatic hypotension
Adrenaline, noradrenaline and dopamine are formed in the body and are used in therapeutics. The natural synthetic path is: tyrosine — dopa — dopamine — noradrenaline — adrenaline.

Given the complexity of critical care practice today, it’s
impossible for even experienced clinicians to remember
all the information required to give safe and effective care
to critically ill patients. Clinicians frequently need to use a
variety of clinical resources to verify drug information,
normal laboratory and physiologic values, ECG and hemodynamic
monitoring information, emergency algorithms,
and other essential facts of patient management.